Is the Level of Pentraxin-3 a Valid Biomarker in Axial Spondyloarthritis?

Abstract

Background Pentraxin-3 (PTX-3) is essential in inflammation, remodelling and regulation of inflammation in various rheumatic diseases. This study aimed to determine whether serum PTX-3 levels indicate increased inflammation and disease activity in patients with axial spondyloarthritis (AxSpA).

Material and Methods The study comprised 50 AxSpA patients and 20 healthy controls (HC). Serum PTX-3, interleukin (IL)-17 and IL-23 levels were compared between AxSpA patients and the control group. The relationship between PTX-3 levels and acute-phase reactants and disease activity was examined. Disease activity was scored using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score-CRP (ASDAS-CRP). Patients with AxSpA were also separated into two subgroups – non-radiographic AxSpA (nr-AxSpA) and radiographic AxSpA (r-AxSpA) – and compared based on their PTX-3 levels. PTX-3, IL-17 and IL-23 levels were measured using the enzyme-linked immunosorbent assay method.

Results PTX-3 levels were higher in patients with AxSpA compared with the HC (2.69±2.03 vs 1.84±1.03 ng/mL, p=0.025). When patients were divided into nr-AxSpA and r-AxSpA subgroups, this difference was found to be only due to patients with r-AxSpA. The r-AxSpA group had significantly higher PTX-3 levels than the nr-AxSpA and HC groups (p=0.020 and p=0.016, respectively). There was no statistically significant difference in PTX-3 levels between the nr-AxSpA and HC groups (p=0.961). There was no correlation between PTX-3 levels and acute-phase reactants, IL-17, IL-23 and disease activity scores (BASDAI and ASDAS-CRP).

Conclusion These findings support the hypothesis that PTX-3 levels are higher in patients with r-AxSpA, where chronic inflammation and structural progression are more pronounced and can be used as an inflammation marker. However, they demonstrate that this relationship does not exist in nr-AxSpA and that there is no correlation between disease activity and PTX-3 levels. Thus, PTX-3 levels may be associated with structural changes.

Key words

Pentraxin-3 - inflammation - interleukin - disease activity - axial spondyloarthritis

Schlüsselwörter

pentraxin-3 - Entzündung - Interleukin - Krankheitsaktivität - Axiale Spondyloarthritis

Publication History

Article published online:
17 January 2023

• References

• 1 McVeigh CM, Cairns AP. Diagnosis and management of ankylosing spondylitis. BMJ. 2006; 333: 581-585
• 2 Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F. Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine 2007; 74: 249-253
• 3 Byravan S, Jain N, Stairs J. et al. Is There a Correlation Between Patient-Reported Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score and MRI Findings in Axial Spondyloarthropathy in Routine Clinical Practice?. Cureus. 2021; 13: e19626
• 4 Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999; 26: 966-970
• 5 Rosa Neto NS, de Carvalho JF, Shoenfeld Y. Screening tests for inflammatory activity: applications in rheumatology. Mod Rheumatol 2009; 19: 469-477
• 6 Ortega-Hernandez OD, Bassi N, Shoenfeld Y. et al. The long pentraxin 3 and its role in autoimmunity. Semin Arthritis Rheum 2009; 39: 38-54
• 7 Bottazzi B, Inforzato A, Messa M. et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol 2016; 64: 1416-1427
• 8 Wu Q, Cao F, Tao J. et al. Pentraxin 3: A promising therapeutic target for autoimmune diseases. Autoimmun Rev 2020; 19: 102584
• 9 Balbaloglu O, Ozcan SS. Is pentraxin 3 level an effective biomarker in disease activity in patients with rheumatoid arthritis?. Arch Med Sci 2019; 16: 81-86
• 10 Muller B, Peri G, Doni A. et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001; 29: 1404-1407
• 11 Rudwaleit M, van der Heijde D, Landewé R. et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection [published correction appears in Ann Rheum Dis. 2019 Jun;78(6):e59]. Ann Rheum Dis 2009; 68: 777-783
• 12 Dougados M, Simon P, Braun J. et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 2011; 70: 249-251
• 13 Poddubnyy D, Rudwaleit M, Haibel H. et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012; 71: 1616-1622
• 14 Deniz T, Kizilgul M, Uzunlulu M. et al. Levels of pentraxin 3 and relationship with disease activity in patients with ankylosing spondylitis. Acta Reumatol Port 2014; 39: 137-142
• 15 Özdemirel AE, Güven SC, Sunar İ. et al. The Relationship between Plasma Pentraxin 3 and Serum Amyloid P Levels and Disease Activity in Ankylosing Spondylitis. Int J Clin Pract 2022; 2022: 7243399
• 16 Nisihara R, Skare TL, Zeni JO. et al. Plasma levels of pentraxin 3 in patients with spondyloarthritis. Biomarkers. 2018; 23: 14-17
• 17 van der Heijde D, Sieper J, Maksymowych WP. et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 905-908
• 18 Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken) 2011; 63: S47-S58
• 19 Doni A, Michela M, Bottazzi B. et al. Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells: stimulation by IL-10 and inhibition by IFN-gamma. J Leukoc Biol 2006; 79: 797-802
• 20 Daigo K, Mantovani A, Bottazzi B. The yin-yang of long pentraxin PTX3 in inflammation and immunity. Immunol Lett 2014; 161: 38-43
• 21 Shiraki A, Kotooka N, Komoda H. et al. Pentraxin-3 regulates the inflammatory activity of macrophages. Biochem Biophys Rep 2016; 5: 290-295
• 22 Jimi E, Takakura N, Hiura F. et al. The Role of NF-κB in Physiological Bone Development and Inflammatory Bone Diseases: Is NF-κB Inhibition “Killing Two Birds with One Stone”?. Cells. 2019; 8: 1636
• 23 Fırat SN, Yazıcı A, Yılmazer B. et al. Low frequency of HLA-B27 in ankylosing spondylitis and its relationship with clinical findings in patients from Turkey. Eur J Rheumatol 2017; 4: 268-271
• 24 Lu CC, Huang GS, Lee TSH. et al. MRI contributes to accurate and early diagnosis of non-radiographic HLA-B27 negative axial spondyloarthritis. J Transl Med 2021; 19: 298